Login to Your Account



Financings Roundup

HemaQuest Expands Series B, Adds $13M for Sickle Cell Drug

By Marie Powers
Staff Writer

Tuesday, March 13, 2012
San Diego biotech HemaQuest Pharmaceuticals Inc. closed a $13 million extension of its Series B financing to fund a Phase IIb study of its lead candidate HQK-1001 in sickle cell disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription